Evidence map›Paper›PMID 40692843›Full record

ArticleFrontiers in toxicology2025

Unlocking liver physiology: comprehensive pathway maps for mechanistic understanding.

Luiz Ladeira, Anouk Verhoeven, Jonas van Ertvelde, Jian Jiang, Alessio Gamba, Julen Sanz-Serrano, Tamara Vanhaecke, Harm J Heusinkveld, Ramiro Jover, Mathieu Vinken and 2 more

Abstract read
In one paragraph

Article in Frontiers in toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Luiz Ladeira *Biomechanics Research Unit, GIGA Institute, University of Liège, Liège, Belgium.
Anouk Verhoeven *Department of Pharmaceutical and Pharmacological Sciences, Entity of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Ixelles, Belgium.
Jonas van ErtveldeDepartment of Pharmaceutical and Pharmacological Sciences, Entity of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Ixelles, Belgium.
Jian JiangDepartment of Pharmaceutical and Pharmacological Sciences, Entity of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Ixelles, Belgium.
Alessio GambaBiomechanics Research Unit, GIGA Institute, University of Liège, Liège, Belgium.
Julen Sanz-SerranoDepartment of Pharmaceutical and Pharmacological Sciences, Entity of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Ixelles, Belgium.
Tamara VanhaeckeDepartment of Pharmaceutical and Pharmacological Sciences, Entity of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Ixelles, Belgium.
Harm J HeusinkveldCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands.
Ramiro JoverDepartment of Biochemistry & Molecular Biology, Exp. Hepatology Joint Unit, University of Valencia, IIS Hospital La Fe, CIBERehd, Valencia, Spain.
Mathieu Vinken *Department of Pharmaceutical and Pharmacological Sciences, Entity of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Ixelles, Belgium.
Liesbet Geris *Biomechanics Research Unit, GIGA Institute, University of Liège, Liège, Belgium.
Bernard Staumont *Biomechanics Research Unit, GIGA Institute, University of Liège, Liège, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Methods: Two PMs were developed through manual literature curation, integrating data from established pathway resources and domain expert knowledge. Cell-type specificity was validated using Human Protein Atlas datasets. An interactive version is available online for exploration. Cross-comparison analysis with existing Adverse Outcome Pathway (AOP) networks was performed to benchmark physiological coverage and identify knowledge gaps. Results: The LiverLipidPM focuses on liver lipid metabolism, detailing pathways involved in fatty acid synthesis, triglycerides, cholesterol metabolism, and lipid catabolism in hepatocytes. And the LiverBilePM represents bile acid biosynthesis and secretion processes, detailing biosynthesis, transport, and secretion processes between hepatocytes and cholangiocytes. Both maps integrate metabolism with signaling pathways and regulatory networks. The interactive maps enable visualization of molecular pathways, linkage to external ontologies, and overlay of experimental data. Comparative analysis revealed unique mechanisms to each map and overlaps with existing AOP networks. Chemical-target queries identified new potential targets in both PMs, which might represent new molecular initiating events for AOP network extension. Conclusion: The developed liver PMs serve as valuable resources for hepatology research, with a special focus on hepatotoxicity, supporting the refinement of AOP networks and the development of human-oriented

Indexed as

hepatologynew approach methodologiesphysiological mapssystems biologytoxicology

Identifiers

PMID40692843
PMCPMC12277266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.